Dabigatran vs Warfarin for Anticoagulation in RFA for AF
In patients undergoing AF ablation, continuation of dabigatran during the periprocedural period is associated with an increased risk of bleeding and composite of bleeding or embolic complications compared with uninterrupted warfarin therapy. Further studies are needed to identify the optimal periprocedural anticoagulation strategies in patients on dabigatran undergoing AF ablation.
Conclusions
In patients undergoing AF ablation, continuation of dabigatran during the periprocedural period is associated with an increased risk of bleeding and composite of bleeding or embolic complications compared with uninterrupted warfarin therapy. Further studies are needed to identify the optimal periprocedural anticoagulation strategies in patients on dabigatran undergoing AF ablation.
Source...